Cytoplasmic dynein is a microtubule-dependent motor protein which participates in numerous cellular processes. The motor complex consists of two heavy chains, intermediate, light intermediate and 3 families of light chains. Dynein is able to bind to these accessory chains as well as to regulatory proteins which enables the motor protein to fulfil such a variety of cellular processes. The associated light chains participate in long-distance organelle and vesicle transport in interphase and in chromosome segregation during mitosis. However, how these light chains control the activity of the motor protein is still unknown. In this study, I combine molecular genetics and live cell imaging to elucidate the role of the associated dynein light intermediate and light chains in dynein behaviour and early endosome (EE) motility in hyphal interphase cells as well as the anchorage of dynein to the microtubule (MT) plus-end in interphase and mitotic cells. I show that the dynein light intermediate chain (DLIC) as well as the light chain 2 (DLC2, Roadblock) are involved in dynein processivity and EE movement in interphase. The downregulation of either protein results in short hyphal growth which could be caused by a decreased runlength of EE and dynein. In addition, both proteins participate in dynein anchorage to the microtubule plus-end in interphase and mitosis as well as in spindle elongation during mitosis. Each protein causes a decrease of the motor protein dynein at MT plus-ends. Surprisingly, I found only minor or no defects in LC8 or Tctex mutants in the observed functions of dynein. LC8 seems to affect the dynein but not the EE runlength. In this case, dynein is still able to move into the bipolar MT array from where kinesin3 is able to take over EEs and move them towards the cell center. In contrast, Tctex has no effect on dynein or EE runlength or any other observed dynein function in hyphal cells. However, it causes a reduction in spindle elongation. Taken together, DLIC and DLC2 are important for dynein behaviour in long distance transport as well as in spindle positioning and elongation during mitosis. Furthermore, I studied the involvement of the dynein regulators Lis1 and NudE as well as the plus-end binding protein Clip1 (Clip-170 homologue) in the anchorage of dynein to the astral microtubule plus-ends during mitosis. The disruption of the anchorage complex at the astral MT plus-end causes a decrease in dynein number at this site and therefore slower spindle elongation in Anaphase B. Taken together, all three proteins are involved in anchorage of dynein to the astral microtubule tip and the subsequent spindle elongation. Furthermore, these findings also show that Ustilago maydis evolved two different mechanisms to anchor the motor protein to MT plus-ends in hyphal and mitotic cells. The plus-end binding protein Peb1 (EB1 homologue) and the dynein regulator dynactin mediate the dynein anchorage in hyphal cells whereas in mitotic cells the plus-ends binding protein Clip1 and the dynein regulators Lis1 and NudE anchor dynein to astral MT plus-ends.

In dieser Arbeit wurden drei verschiedene Gruppen von humanen Myokardproben aus dem interventrikulären Septum mittels elektrophoretischer Verfahren auf Veränderungen in der Zusammensetzung der kontraktilen Proteine untersucht. 6 der insgesamt 38 Proben stammten von gesunden Herzen, die aus technischen Gründen nicht transplantiert werden konnten. 19 der Proben stammten von Patienten, die an einer hypertrophischen-obstruktiven Kardiomyopathie (HOCM) litten und die restlichen 13 Proben von Patienten mit einer valvulären Aortenstenose (AS). Die 32 kranken Herzen befanden sich allesamt im Stadium der kompensierten Hypertrophie, an klinischen Daten waren von diesen Patienten die Ejektionsfraktion (EF), der Durchmesser des interventrikulären Septums (IVS) sowie die linksventrikuläre enddiastolische Füllungsdruck (LVEDP). Die Ejektionsfraktion lag bei allen diesen Patienten mit Werten zwischen 62% und 88% (Mittelwert 73 ± 7%) im Normbereich, zwischen der HOCM- und der Aortenstenosegruppe bestand kein signifikanter Unterschied. Die insgesamt 38 Gewebeproben wurden mittels 3 verschiedener elektrophoretischer Verfahren auf das Vorliegen von 3 verschiedener Veränderungen in der Proteinzusammensetzung untersucht: 1. Mittels 2-dimensionaler Polyacrylamidgel-Elektrophorese (2D-PAGE) wurde der Phosphorylierungsgrad des kardialen Troponin I (cTnI) bestimmt. 2. Mittels 2-dimensionaler Polyacrylamidgel-Elektrophorese (2D-PAGE) wurde eine Analyse der leichten Myosinketten (MLC) durchgeführt, vor allem im Hinblick auf die Frage, ob und inwieweit es zu einer Expression der atrialen leichten Kette vom Typ I (ALC-1) kommt . 3. Mittels Natriumdodecylsulfat-Polyacrylamidgel-Elektrophorese (SDS-PAGE) wurde eine Bestimmung der schweren Myosinketten (MHC) vorgenommen, vor allem im Hinblick auf die Frage, ob es im hypertrophierten Myokard zu einer Expression der α-Isoform der schweren Myosinkette (α-MHC) kommt. Für alle dieser drei oben genannten Veränderungen finden sich Hinweise in der Literatur, dass sie möglicherweise eine Rolle bei der Myokardhypertrophie spielen könnten ohne dass bislang eine abschließende Klärung möglich war. In dieser Arbeit wurde zum ersten Mal ein derartig großes, klinisch gut evaluiertes Probenkollektiv von menschlichen Herzen im Stadium der kompensierten Hypertrophie auf das Vorliegen der o.g. Veränderungen untersucht. Ein weiterer wichtiger Aspekt ist das Vorliegen von zwei verschiedenen Ursachen (Aortenstenose und hypertrophisch-obstruktive Kardiomyopathie) für die Herzhypertrophie im Probenkollektiv dieser Arbeit. In der Zusammensetzung der schweren Myosinketten (MHC) sowie im Phosphorylierungsgrad des kardialen Troponin I (cTnI) konnten in dieser Arbeit keine signifikanten Unterschiede zwischen dem hypertrophiertem und dem gesunden Myokard gefunden werden. Im Bereich der leichten Myosinketten (MLC) konnte jedoch nachgewiesen werden, dass es in den hypertrophierten Herzen zu einer deutlichen, signifikanten Expression der atrialen leichten Myosinkette (ALC-1) in der Größenordnung von 10,8 ± 1,5 % an der Gesamtmenge der leichten Myosinketten vom Typ 1 (MLC-1) gekommen war. Im Gegensatz hierzu konnte die atriale leichte Kette vom Typ 1 (ALC-1) in keinem der gesunden Herzen nachgewiesen werden. Zudem konnte eine statistische hochsignifikante positive Korrelation (Koeffizient 0,56 nach Pearson) zwischen der Höhe der Ejektionsfraktion und dem Anteil der ALC-1 an der Gesamtmenge der leichten Myosinketten ermittelt werden. Diese Ergebnisse legen nahe, dass der Expression der ALC-1 ein hoher Stellenwert bei der Anpassung an erhöhte hämodynamische Anforderungen zukommt. Die positive Korrelation zwischen der Höhe der ALC-1-Expression und der Ejektionsfraktion weisen daraufhin, dass der ALC-1-Expression zumindest im Rahmen der kompensierten Hypertrophie ein positiver Effekt auf das Myokard zukommt. Dieser Effekt lässt sich anhand von früheren Veröffentlichungen erklären, die z.B. zeigten, dass die ALC-1 über eine Erhöhung der Ablösungsgeschwindigkeit zu einer Beschleunigung des Querbrückenzyklus und zu einer Erhöhung der Verkürzungsgeschwindigkeit und der isometrischen Kraftentwicklung führt. / To assess changes in the composition of contractile proteins we examined human myocardial samples from three different groups by means of electrophoretic analysis. 6 of 38 samples in total have been taken from healthy hearts which could not be transplanted due to technical reasons. 19 of the samples are from patients suffering from hypertophic obstructive cardiomyopathy and the remaining 13 samples from patients with a valvular aortic stenosis. The 32 impaired hearts have all been in the stadium of compensated hypertrophy, the ejection fraction, the diameter of the interventricular septum and the leftventricular enddiastolic pressure were kown. In all patients the ejection fraction was between 62% and 88% (73 ± 7% in the mean), thus in the normal range, there was no significant difference between the hypertrophic obstructive group and the valvular aortic stenosis group. All of the 38 samples have been examined by means of 3 different electrophoretical procedures. 1. 2-dimensional polyacrylamide gelelectrophoresis (2D-PAGE) for assessing the level of phosphorylation of the cardial troponin I(cTnI) 2. 2-dimensional polyacrylamidegelelectrophoresis (2D-PAGE) for analysing the composition of the myosin light chains (MLC)to answer the question whether there is an reexpression of the atrial light chain 1 (ALC-1) and if, to which extent. 3. Sodiumdodecylsulfate polyacrylamide gelelectrophoresis (SDS-PAGE) to assess the composition of the myosin heavy chains to answer the question whether there is an expression of the α-Isoform of the myosin heavy chain (α-MHC)in the hypertrophic myocardium. There are hints in literature that all 3 changes mentioned above could play a role in myocardial hypertrophy but it has not been possible to definitely clarify the role. We have analysed for the first time a great number of clinically well evaluated samples from hypertrophic human hearts in the stadium of compensated hypertrophy regarding those changes. Another important aspect of our work is that in our samples the cause of the hypertrophy have been two pathogenetically different diseases (valvular aortic stenosis and hypertrophic obstructive cardiomyopathy). We could not find any significant differences between the hypertrophic and the nonhypertrophic hearts regarding the level of phosphorylation of the cardial troponin I (cTnI). We proved that in the hypertrophic heart there is a significant expression of the atrial light chain 1 (ALC-1) of about 10,8 ± 1,5 % of the total amount of myosin light chain 1 (MLC-1). In contrast to that there was no atrial light chain 1 (ALC-1) found in the nonhypertrophic hearts. Statistically there is a highly significant correlation (coefficient 0,56 after Pearson) between the level of the ejection fraction and the amount of the atrial light chain 1 (ALC-1) compared to the myosin light chain 1 (MLC-1) in total. These results suggest a highly important role of the ALC-1 expression in the adjustment of the heart to increased hemodynamic demands. The positive correlation between the level of the ALC-1 expression and the level of the ejection fraction suggests a positive effect of the ALC-1 expression on the myocardium during compensated hypertrophy. This effect can be explained by former publications which have shown that the expression of the ALC-1 can lead to an increased speed of displacement hence to an increased shortening velocity and an increased isometric force generation.

Cardiac muscle contraction is responsible for pumping blood throughout the body. The cyclical, ATP-hydrolysis dependent interaction of the myosin motor protein with filamentous actin drives muscle contraction. During this process the α-helical neck region of myosin acts as a lever arm, transmitting contractile force between thick and thin filaments by amplifying small conformational changes in the myosin motor domain. The resulting relative displacement of thick and thin filaments causes muscle shortening. The regulatory light chain (RLC) of myosin mechanically supports the lever arm by binding to the myosin heavy chain neck region; this is a crucial interaction in maintaining myosin's ability to produce force and motion. We investigated the role of N-terminal modifications of the RLC in modulating actomyosin contractility at the molecular level. Phosphorylation of the RLC is a naturally occurring post-translational modification of the RLC N-terminus that is important for cardiac function and has been shown to enhance contractility at the cellular level. In contrast, genetic mutations of the RLC that lead to familial hypertrophic cardiomyopathy (FHC) disrupt cardiac function and trigger remodeling of the cardiac muscle structure. We studied two FHC-linked mutations, N47K and R58Q, located in the N-terminus of the RLC in close proximity to the phosphorylation site. Using in vitro motility assays we examined how RLC modifications affect the mechanochemical properties of cardiac β-myosin. We found that the FHC mutations reduced myosin force and power generation, in contrast to RLC phosphorylation which increased myosin force and power for WT and mutant myosins. Phosphorylation of mutant RLC resulted in a restoration of the mutation-induced decreases in contractility to WT dephosphorylated levels. These results point to RLC phosphorylation as a general mechanism to increase force production of the individual myosin motor and as a potential target to ameliorate the fundamental contractile FHC-induced phenotype.

Human immunodeficiency virus type 1 (HIV-1) infection causes general loss of immune response in humans. Presently, an estimated 34 million (31.4-35.9 million) people worldwide are HIV-1 positive and many more are being newly infected. In the absence of a definitive cure, anti-HIV-1 drug therapy helps to manage the infection by suppressing virus replication. However, extensive drug resistance against most of existing drugs demands alternative anti-HIV-1 strategies. The proper knowledge about HIV-1 replication is essential to guide the development of new anti-HIV-1 strategies. The research presented in this thesis aims to understand the role of HIV-1 Integrase (IN) and cellular co-factors interactions in the early stage virus replication. In the cytoplasm, HIV-1 cDNA exists as a high molecular weight nucleoprotein complex called pre-integration complex (PIC). The cDNA enters the nucleus as a part of PIC by active nuclear import and integrates into the host genome. HIV-1 Integrase (IN) protein has been recognized as a primary viral factor for HIV-1 nuclear import, but the key contributing cellular factor(s) is unknown. We have examined the requirement of different Importinα (Impα) isoforms for HIV-1 replication and identified the requirement of Impα3 for HIV-1 replication in HeLa cells, C8166T cells, and human macrophages. Further investigations showed the specific requirement of Impα3 for HIV-1 nuclear import. By analyzing the Impα3 interaction with HIV-1 proteins, we detected the IN interaction with Impα3 and C-terminal domain (CTD) of IN was essential for Impα3 interaction. These data led to the conclusion that Impα3 is required for HIV-1 nuclear import and interacts with IN. The IN-CTD consists of conserved basic amino acid rich motifs (211KELQKQITK, 236KGPAKLLWK, and 262RRKAK) that closely resemble the consensus classical nuclear localization signal (NLS) for Impα interaction. By substitution mutation and interaction analysis, 211KELQKQITK and 262RRKAK motifs in IN were identified as required for Impα3 interaction, IN nuclear localization, and HIV-1 nuclear import. Together, these data were useful in explaining the molecular mechanism of IN and Impα3 interaction and its requirement for HIV-1 nuclear import. Retrograde transportation of macromolecules in the cytoplasm is one of the prerequisites for their nuclear import. Although an earlier study implicated the dynein complex in retrograde transport of HIV-1, cellular and viral factors that are involved in this process are unknown. In this study, we have elucidated the HIV-1 IN interaction with the dynein light chain 1 (DYNLL1) in 293T cells, in vitro, and in HIV-1 infected cells. DYNLL1 is one of the adapter proteins that mediate the cargo recruitment to dynein complex. However, our data suggested that the IN and DYNLL1 interaction is essential for proper HIV-1 uncoating and cDNA synthesis but not for nuclear import. Surprisingly, DYNLL1 interaction of IN was dispensable for HIV-1 recruitment to dynein complex. These data led to the conclusion that the IN and DYNLL1 interaction is essential for proper HIV-1 uncoating and cDNA synthesis but not required for HIV-1 recruitment to the dynein complex or for retrograde transport. In summary, this study advances our knowledge on the role of IN and cellular factors interactions in different early steps of HIV-1 replication and offers potential contributions in the development of future anti-HIV-1 strategies.

A major contributor to mortality in patients with plasma cell dyscrasias (PCDs); i.e., multiple myeloma, light chain deposition disease and AL amyloidosis is the deposition as insoluble aggregates of monoclonal immunoglobulin light chain proteins (LC) in the kidneys and other organs. Currently anti-plasma cell chemotherapies are used to reduce LC synthesis, and slow deposition. While effective, these treatments are toxic, non-specific, expensive, and might not be appropriate in all cases, making the identification of an alternate means of reducing toxic LC species desirable. To this end, we have investigated whether RNA interference (RNAi) could achieve these goals. Human (RPMI 8226, Bur) and transfected mouse myeloma (SP2/O-lambda 6) cells which produce measureable quantities of human LC protein were used as model systems for testing the efficacy of both synthetic small interfering RNAs (siRNAs) and short hairpin RNA (shRNA) expression vectors in reducing LC synthesis. Sequencing of LC genes provided the basis for design of siRNA duplexes targeting either the variable (V) or joining (J) regions of individual LCs, or the constant (C) region of either kappa or lambda LC isotypes. Myeloma lines were transfected with siRNAs using lipid-based transfection media. Cells receiving non-silencing siRNAs served as controls. Exposure of myeloma lines to siRNAs was well tolerated and no cytotoxicity was observed. LC mRNA expression was shown to be reduced ≥40% in 8226 and SP2/O- lambda 6 cell lines receiving siRNA treatment as compared with untreated controls. Exposure to siRNAs was also effective in significantly reducing both intracellular and secreted LC protein levels in cell lines tested as evidenced by flow cytometry or enzyme-linked immunosorbent assays (ELISAs). Effective siRNA nucleotide sequences were used to generate shRNA cassettes which were ligated into lentiviral expression vectors under the control of the RNA polymerase III promoter, U6. These expression systems were used to generate replication incompetent lentiviral particles. Exposure of 8226 to lentiviral particles resulted in significant knockdown of LC mRNA and protein both in vitro and in xenograft tumor bearing immune compromised mice. These results provide positive evidence for the ability of RNAi based approaches to reduce LC secretion in models of PCD.

No description available.

Thesis (Ph.D.) -- University of Texas Southwestern Medical Center at Dallas, 2005. / Embargoed. Vita. Bibliography: 97-123.

Multiple sclerosis is chronic, autoimmune and neurodegenerative disorder of central nervous system. Currently, we have only limited markers of disease activity. From clinical markers, speech markers were analysed. Data from 141 patients and 70 healthy controls were evaluated. The most important results were detection of speech abnormalities in patients with minimal neurological disability (EDSS<2) and their correlations with global and regional brain atrophy. This work is predominantly concetrated on neurofilament light chain (NfL) as one of the most promising paraclinical biomarkers. NfL, especially level of serum NfL (sNfL), is considered to be a biomarker of future disease course, disease activity and effect of DMD (disease modifying drugs) therapy. The main aim was to clarify the position of NfL among others biomarkes and their potential benefit for routine clinical praxis. MRI data, clinical data and results of NfL measurements from 172 newly diagnosed patients with relaps-remiting MS (revised McDonald criteria 2017) from original SET cohort were analysed. Additionally, we compared levels of serum and CSF NfL with other biochemical parameters, such as lipidogram and markers of blood-brain permeability. We found sNfL as a marker of ongoing neuroinflammation and predictor of future brain atrophy...

Spider silk has received significant attention due to its fascinating mechanical properties. Given the solitary and cannibalistic behavior of spiders, spider silk farming is impractical. Unlike spiders, silkworms are capable of producing large quantities of a fibrous product in a manner mimetic to spiders, and there already exists an industry to process cocoons into threads and textiles for many applications. The combination of silk farming (sericulture), a millennia old practice, and modern advancements in genetic engineering has given rise to an innovative biomaterial inspired by nature; transgenic silkworm silk. This project focuses on the creation of chimeric silkworm-spider silk fibers through the genetic modification of silkworms. Advanced genetic engineering techniques were used to introduce the minor ampullate spider silk (MiSp) genes into the silkworm genome. A subset of these transgenic silkworms was cross-bred with other transgenic silkworms containing the same spider silk gene in a different section of the silkworm genome to create hybrid, dual-transgenic silkworms. The transgenic silk samples showed increased mechanical properties compared to native silkworm fibers, with the strongest fibers approaching or surpassing the mechanical properties of native spider silk. The transgenic silk retained the elasticity of the native silkworm silk and gained the strength of the spider silk. Ultimately, genetic engineering opens the door to mass produce synthetic spider silk in an established organism and industry, and the results of this project demonstrate that the properties of silkworm silk can be predictably altered through this technology.

Light Chain Deposition Disease (LCDD) is a type of monoclonal immunoglobulin deposition disease characterized by the non-amyloid deposition of monoclonal light chains in the tubular basement membranes and Bowman’s capsule. It was first described about 3 decades ago, but due to varied clinical presentations, many differential diagnoses and low incidence, it is both underrecognized and underreported. We present a case of 85-year-old female with past medical history significant for CKD and HTN, who presented with accelerated HTN, normocytic anemia and worsening renal function. Laboratory data showed Hgb <9.5 gm/dL, MCV 93 fL, Total protein 5.9, Albumin 3.2, Calcium 8.9, Serum Creatinine 2.37, BUN 45, Urine with hematuria (50–99 erythrocytes per high-power field) and nephrotic range proteinuria. Renal biopsy showed evidence of Membranoproliferative glomerulonephritis, with immunofluorescence features indicative of a monoclonal immunoglobulin deposition disease. Bone marrow biopsy showed mildly increased plasma cells (5-7%) confirmed to be clonal (lambda light chain) by flow cytometry, negative for Congo-Red stain. Although no underlying hematological abnormality like Multiple Myeloma or Amyloidosis was observed in this case, the renal pathological findings is consistent with proliferative glomerulonephritis with monoclonal IgG lambda deposits. There is no standard of care for the management of LCDD based on rarity of this condition. Many treatment modalities including chemotherapy and stem cell transplant have been tried. A combination of high dose melphalan or Cyclophosphamide with dexamethasone is preferred for Non-IgM type monoclonal protein kidney deposition, like in this case. Bortezomib and Thalidomide-based chemotherapy have been promising in recent research. For IgM type monoclonal protein deposition, Rituximab alone or in combination with cyclophosphamide and dexamethasone are used. This patient was not a good candidate for corticosteroid and chemotherapy or stem cell transplant due to old age (>77 years) and poor functional status, therefore, was started on hemodialysis. Following dialysis, improvement in renal function and general clinical condition was evident. The prognostic factors include age, degree of renal insufficiency at presentation affecting the renal prognosis, underlying hematologic disorder and extrarenal LC deposition. In this case, despite hemodialysis, long term survival and prognosis remain poor due to her inability to tolerate chemotherapy.